Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through the R&D spending tables, clinical trial risk factors, and patent disclosures in SAB Biotherapeutics’ filings can feel like a second job. Because the company’s DiversitAb platform—powered by transchromosomic cattle—creates complex revenue pathways and milestone obligations, each report runs deep with technical detail. Our SEC dashboard tackles that challenge head-on by turning every form into plain language insights, so understanding SAB Biotherapeutics SEC documents with AI becomes routine rather than daunting.
Whether you are scanning a SAB Biotherapeutics quarterly earnings report 10-Q filing for cash-burn trends, or need a SAB Biotherapeutics annual report 10-K simplified to spot pipeline progress on SAB-142, Stock Titan delivers. Real-time alerts surface SAB Biotherapeutics Form 4 insider transactions real-time, letting you track executive sentiment the moment it posts to EDGAR. You can also dive into SAB Biotherapeutics insider trading Form 4 transactions histories, compare option grants in the latest SAB Biotherapeutics proxy statement executive compensation, and read our AI-generated notes on every SAB Biotherapeutics 8-K material events explained—from trial readouts to capital raises.
Behind the scenes, our algorithms map each note, covenant, and clinical update to the metrics analysts care about most. That means instant SAB Biotherapeutics earnings report filing analysis that highlights gross R&D spend, runway projections, and partnership revenue. With comprehensive coverage of all forms—including 10-K, 10-Q, 8-K, S-3, and every SAB Biotherapeutics executive stock transactions Form 4—you get the clarity you need without paging through dense biotech disclosures. Complex filings, explained simply.
SAB Biotherapeutics, Inc. Schedule 13G filings show affiliated Vivo Opportunity entities report beneficial ownership tied to convertible Series B Preferred Stock, Enrollment Warrants and Data Release Warrants. On September 29, 2025 4,401,500 shares of Common Stock were converted automatically from Series B Preferred Stock (4,000,000 and 401,500 shares by two Vivo groups). The filings report an aggregate of 25,931,000 shares attributable to Vivo Opportunity Fund Holdings/manager entities and 2,619,000 shares attributable to Vivo Opportunity Cayman entities, each disclosed as representing 9.99% of the class. Many additional shares are reported as issuable upon conversion/exercise within 60 days, but the securities include blocking provisions that prevent conversion or exercise that would raise ownership above 9.99%. Signatures show the filings were executed by Kevin Dai on October 3, 2025.
RA Capital and affiliated persons report owning 4,401,500 shares of SAB Biotherapeutics common stock, representing 9.99% of the outstanding shares following an automatic conversion tied to a private placement.
The position arose from the Fund's purchase of 171,400 Series B Preferred Shares on July 22, 2025 at $175 per share (aggregate $29,995,000). Upon stockholder approval at a special meeting, 44,015 Preferred Shares converted into 4,401,500 common shares. The Preferred Stock includes a Beneficial Ownership Blocker preventing conversion above 9.99% (adjustable up to 19.99% with 61 days' notice).
Commodore Capital LP and related filers report beneficial ownership of 4,522,977 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the outstanding class based on 45,108,294 shares reported by the issuer. The position includes 4,401,500 shares issued to Commodore Capital Master LP upon conversion of Series B Convertible Preferred Stock after stockholder approval on September 26, 2025, plus 121,477 additional shares issuable upon conversion but subject to a 9.99% ownership limitation (the "Ownership Blocker"). The filing discloses that larger pools of shares issuable on conversion and under warrants are excluded from the reported aggregate because they are constrained by the Ownership Blocker. Voting and dispositive power over the reported shares is shared among the filers; no filer reports sole voting or dispositive power.
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Sessa Capital reported the automatic conversion of Series B Convertible Preferred Stock into common stock of SAB Biotherapeutics (SABS) on 09/29/2025. The filing shows the Fund received 1,740,000 common shares as a result of converting 17,400 preferred shares at an effective price of $1.75 per share. The Fund originally acquired the preferred shares for an aggregate purchase price of $39,987,500 under a July 21, 2025 purchase agreement. After the conversion, the reporting persons collectively beneficially owned 2,198,457 shares of common stock. The conversion is subject to a 4.99% beneficial ownership limitation that restricts further conversions that would exceed that threshold.
SAB Biotherapeutics describes clinical and corporate disclosures in this amended shelf filing. The filing reports that SAB-142 showed a favorable safety profile in Phase 1 across a dose range of 0.03 mg/kg to 2.5 mg/kg, with 0% reported serum sickness and 0% reported anti-drug antibodies, supporting chronic ambulatory dosing. The company states SAB-142 demonstrated sustained immunomodulation and a multi-target mechanism of action analogous to rabbit ATG on parameters correlative to C-peptide preservation.
The prospectus reiterates extensive risk-factor topics and lists permitted methods for secondary distributions by selling stockholders. It also references recent SEC filings, including the 2024 annual report and quarterly and current reports filed in 2025, without providing financial results in the included excerpt.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?
What is the market cap of SAB BIOTHERAPEUTICS (SABS)?
